Compare LMRI & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMRI | SPTX |
|---|---|---|
| Founded | 2018 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 929.8M |
| IPO Year | 2025 | 2026 |
| Metric | LMRI | SPTX |
|---|---|---|
| Price | $14.92 | $19.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $17.67 | ★ $37.13 |
| AVG Volume (30 Days) | ★ 377.9K | 235.0K |
| Earning Date | 11-10-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.38 | N/A |
| Revenue Next Year | $5.55 | N/A |
| P/E Ratio | $125.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.45 | $15.79 |
| 52 Week High | $19.45 | $28.38 |
| Indicator | LMRI | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 73.42 | 46.86 |
| Support Level | $13.85 | $18.79 |
| Resistance Level | $16.38 | $22.53 |
| Average True Range (ATR) | 0.80 | 1.46 |
| MACD | 0.36 | 0.01 |
| Stochastic Oscillator | 71.74 | 22.55 |
Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities, including MRI, CT, PET, X-ray, ultrasound, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated by the Outpatient segment, which performs imaging studies and provides radiologists' interpretations of those studies.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.